News China’s BeiGene delays US filing for rival to Imbruvica BeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s blockbuster Imbruvica have suffered a setback.
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
